Predictive factors of radioiodine therapy failure in Graves’ Disease: A meta-analysis - 10/02/22
![](/templates/common/images/mail.png)
Abstract |
Background |
I-131 therapy is a common treatment modality for adults with Graves’ Disease (GD). Utilizing meta-analysis, we examined patient specific factors that predict I-131 therapy failure.
Methods |
Literature search followed PRISMA. Comprehensive Meta-analysis (version 3.0) was used. Mantel-Haenszel test with accompanying risk ratio and confidence intervals evaluated categorical variables. Continuous data was analyzed using inverse variance testing yielding mean difference or standardized mean difference. Decision tree algorithms identified variables of high discriminative performance.
Results |
4822 collective patients across 18 studies were included. Male sex (RR = 1.23, 95%CI = 1.08–1.41, p = 0.002), I-131 therapy 6 months after GD diagnosis (RR = 2.10, 95%CI = 1.45–3.04, p < 0.001) and history of anti-thyroid drugs (RR = 2.05, 95%CI = 1.49–2.81, p < 0.001) increased the risk of I-131 therapy failure. Elevated free thyroxine, 24-h radioactive iodine uptake scan ≥60.26% and thyroid volume ≥35.77 mL were also associated with failure.
Conclusion |
Patient characteristics can predict the likelihood of I-131 therapy failure in GD. Definitive surgical treatment may be a reasonable option for those patients.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Patient characteristics can predict the likelihood of I-131 therapy failure. |
• | I-131 uptake of ≥60.26% and thyroid volume ≥35.77 mL are therapy failure predictors. |
• | Radioactive iodine dose has no significant association with treatment outcome. |
Keywords : Graves’ disease, Thyroid diseases, Radioactive iodine, Iodine therapy, Meta-analysis
Plan
Vol 223 - N° 2
P. 287-296 - février 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?